Immunotherapy plus chemotherapy before and after surgery for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether combining the immunotherapy drug tislelizumab with chemotherapy before and after surgery helps treat esophageal squamous cell cancer better than just surgery alone. It aims to shrink the tumor before surgery and reduce the chance of the cancer coming back afterward.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have been diagnosed with squamous cell esophageal cancer, and it must be in a certain stage (cT3-4aN0M0 or cT1b-4aN+M0) that has not spread far beyond the chest area.
- You need to be in fairly good physical condition, with a score of 0 or 1 on the ECOG scale (meaning you can take care of yourself and are up and about).
- Your major organs must be working well enough — this will be checked with blood tests for blood cell counts, liver and kidney function.
- You must not have had prior treatment for this cancer with immunotherapy, chemotherapy, radiation, or surgery that removes the tumor.
- You must not have an active autoimmune disease, uncontrolled infection, or serious heart problems.
- If you've been treated for cancer, it must not have been with certain other investigative drugs in the last 4 weeks.
- You should not have gotten a live vaccine within 28 days of the study start.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new immunotherapy drug (tislelizumab) combined with chemotherapy before either surgery or radiation for esophageal cancer. The goal is to see if this combination helps shrink the tumor and improves outcomes, and it may offer a promising option for patients who meet the criteria.
This trial tests whether giving an immunotherapy drug called tislelizumab before surgery helps shrink esophageal cancer and improve outcomes. It is for people newly diagnosed with early-stage squamous cell esophageal cancer that can be removed surgically.
This trial tests a combination of treatments given before surgery to shrink tumors in patients with esophageal cancer that is considered too advanced for immediate surgery. The goal is to make surgery possible and improve outcomes.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of chemotherapy, immunotherapy, and a type of radiation that avoids nearby lymph nodes, given before surgery for a specific stage of esophageal cancer. The goal is to see if this approach can improve outcomes and make surgery more effective.
This trial tests combining a type of immunotherapy (adebrelimab) with chemotherapy before surgery, for esophageal cancer that can be removed. The goal is to see if this combo helps shrink the tumor and improve outcomes.
Hear when a new Esophagus Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.